4-Methyl-6,7-dihydro-4<i>H</i>-triazolo[4,5-<i>c</i>]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate

Michael A. Letavic(Janssen (United States)), Anindya Bhattacharya(University of York), Ian Fraser(Janssen (United States)), Stewart Bryant(Janssen (United States)), Marc Ceusters(Janssen (Belgium)), Brad M. Savall(Janssen (United States)), Pascal Bonaventure(Janssen (United States)), Nicholas I. Carruthers(Io Therapeutics (United States)), Devin M. Swanson(Janssen (United States)), Curt A. Dvorak(Janssen (United States)), Hong Ao(Janssen (United States)), Monicah A. Otieno(Springhouse), Brett D. Allison(Janssen (United States)), Meri De Angelis(Helmholtz Zentrum München), Christine F. Gelin(Janssen (United States)), Leah Aluisio(Janssen (United States)), Brian Lord(Janssen (United States)), Freddy Schoetens(Janssen (United States)), Jimmy T. Liang(Janssen (United States)), Qi Wang(Hebei Medical University), José Ignacio Andrés, Alan D. Wickenden(Janssen (United States)), Tatiana Koudriakova(Janssen (United States)), Derek A. Beauchamp(Janssen (United States)), Timothy W. Lovenberg(Janssen (Belgium)), Kevin J. Coe(Janssen (United States))
Journal of Medicinal Chemistry
May 11, 2017
Cited by 69


Related Papers